Home › Therapeutic areas › Infectious Disease

Infectious Disease (21 companies · 24 conditions)

Conditions

Companies

Ticker Company Therapeutic areas In Infectious Disease Lead stage Mkt cap Programs
ADMA Adma Biologics ImmunologyInfectious Disease Rare 2 Approved $3.02B 4
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare 3 Phase 2 $161M 6
BCRX Biocryst Pharmaceuticals DermatologyImmunology+1 Rare 1 Approved $1.93B 4
CAPR Capricor Therapeutics Infectious DiseaseNeurology Rare 1 NDA Submitted $489M 2
ENTA Enanta Pharmaceuticals DermatologyImmunology+2 5 Approved $253M 8
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 1 Approved $1.84B 17
FBIO Fortress Biotech DermatologyHematology+4 Rare 1 Approved $61.4M 16
IBRX ImmunityBio Infectious DiseaseOncology 1 Approved $6.66B 17
IMCR Immunocore DermatologyInfectious Disease+2 2 Approved $1.44B 12
INSM Insmed CardiovascularImmunology+3 Rare 3 Approved $26.7B 15
IVVD Invivyd Infectious Disease 4 Approved $152M 5
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 1 Approved $4.49B 29
OCGN Ocugen Infectious DiseaseOphthalmology Rare 4 Phase 3 $257M 12
PYPD PolyPid Infectious DiseaseMetabolic+1 1 NDA Submitted $138M 4
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare 1 Phase 1 $197M 5
SCYX Scynexis Infectious DiseaseRenal Rare 4 Approved $28.4M 5
TTRX Turn Therapeutics DermatologyInfectious Disease Rare 1 Phase 2 $261M 4
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 1 Approved $230M 27
PCVX Vaxcyte Infectious Disease 6 Phase 3 $9.40B 7
VERA Vera Therapeutics Infectious DiseaseRenal Rare 1 Approved $1.89B 6
VIR Vir Biotechnology Infectious DiseaseOncology Rare 2 Phase 3 $1.58B 6